Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study

Multiple Sclerosis Journal

Volumn 21, Issue 2, 2015, Pages 198-205

  Ebrahimi, Neda ^a,b   Herbstritt, Sandra ^c   Gold, Ralph ^c   Amezcua, Lilyana ^d   Koren, Gideon ^a,b   Hellwig, Kerstin ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST JOSEF HOSPITAL   (Germany)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Fetal safety; Multiple sclerosis; Natalizumab; Pregnancy exposure

Indexed keywords

BENDECTIN; BETA1A INTERFERON; DIMENHYDRINATE; GINGER EXTRACT; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PYRIDOXINE; STEROID; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; GERMAN (CITIZEN); GINGER; GROWTH RETARDATION; HUMAN; LIVE BIRTH; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; RISK ASSESSMENT; SPONTANEOUS ABORTION; STEROID THERAPY; TREATMENT DURATION; VAGINAL DELIVERY; DRUG EFFECTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS;

ADULT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST;

EID: 84923090375     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514546790     Document Type: Article

References (18)

1. Chataway J, Miller DH. Natalizumab therapy for multiple sclerosis. Neurotherapeutics. 2013 ; 10: 19-28
2. Wehner NG, Gasper C, Shopp G, et al. Immunotoxicity profile of natalizumab. J Immunotoxicol. 2009 ; 6: 115-129
3. Wehner NG, Shopp G, Rocca MS, et al. Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 86: 98-107
4. Wehner NG, Shopp G, Osterburg I, et al. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 86: 144-156
5. Wehner NG, Shopp G, Oneda S, et al. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 86: 117-130
6. Friend S, Richman S, Bozic C, et al. Evaluation of pregnancy outcomes from the TYSABRI (natalizumab) pregnancy exposure registry.. 2013 ; 80 (Meeting Abstracts 1). P02.127
7. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011 ; 17: 958-963
8. Fox RJ, Cree BA, De Seze J, et al. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Neurology. 2014 ; 82: 1491-1498
9. Bayas A, Penzien J, Hellwig K. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis. Acta Neurol Scand. 2011 ; 124: 290-292
10. Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: Population based register linkage study. BMJ. 2000 ; 320: 1708-1712
11. Dahl J, Myhr KM, Daltveit AK, et al. Planned vaginal births in women with multiple sclerosis: Delivery and birth outcome. Acta Neurol Scand Suppl. 2006 ; 183: 51-54
12. Dahl J, Myhr KM, Daltveit AK, et al. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol. 2008 ; 255: 623-627
13. Chan RL, Olshan AF, Savitz DA, et al. Maternal influences on nausea and vomiting in early pregnancy. Matern Child Health J. 2011 ; 15: 122-127
14. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology. 2012 ; 79: 1130-1135
15. Voigt M. Analyse des neugeborenenkollektivs der Bundesrepublik deutschland. 12. mitteilung: Vorstellung engmaschiger perzentilwerte (-kurven).für die körpermaße neugeborener. geburtsh frauenheilk. Geburtsh Frauenheilk. 2006 ; 66: 956-970
16. Public Health Agency of Canada. Birth weight for gestational age, http://www.phac-aspc.gc.ca/rhs-ssg/bwga-pnag/ (2004, accessed October 1, 2013).
17. Singh S, Sedgh G, Hussain R. Unintended pregnancy: Worldwide levels, trends, and outcomes. Stud Fam Plann. 2010 ; 41: 241-250
18. Jauniaux E, Jurkovic D, Gulbis B, et al. Materno-fetal immunoglobulin transfer and passive immunity during the first trimester of human pregnancy. Hum Reprod. 1995 ; 10: 3297-3300